key: cord-1022052-d6nfuv85
authors: Kim, Ha Nui; Yoon, Soo‐Young; Lim, Chae Seung; Yoon, Jung
title: Comparison of three molecular diagnostic assays for SARS‐CoV‐2 detection: Evaluation of analytical sensitivity and clinical performance
date: 2022-01-12
journal: J Clin Lab Anal
DOI: 10.1002/jcla.24242
sha: 8c9542a8c388c3b79d50b9879dce3c7fba654b7f
doc_id: 1022052
cord_uid: d6nfuv85

BACKGROUND: Currently, SARS‐CoV‐2 RNA detection using real‐time reverse‐transcription PCR (rRT‐PCR) is the standard diagnostic test for COVID‐19 infection. Various rRT‐PCR assays are currently used worldwide, targeting different genes of the SARS‐CoV‐2. Here, we compared the analytical sensitivity and clinical performance (sensitivity and specificity) of Allplex SARS‐CoV‐2/FluA/FluB/RSV assay (Seegene), Standard M nCoV real‐time detection kit (SD Biosensor), and U‐TOP COVID‐19 detection kit (Seasun Biomaterials) for SARS‐CoV‐2 detection. METHODS: Two hundred and forty‐nine nasopharyngeal swab samples were evaluated to compare the clinical performance of the rRT‐PCR assays. For the analytical performance evaluation, two RNA controls with known viral loads—SARS‐CoV‐2 RNA control and SARS‐COV‐2 B.1.351 RNA control—were used to investigate the potential impact of SARS‐CoV‐2 variants, particularly the B.1.351 lineage. RESULTS: Limits of detection ranged from 650 to 1300 copies/ml for rRT‐PCR assays, and the mean differences in cycle threshold (C (t) ) values of the two RNA controls were within 1.0 for each target in the rRT‐PCR assays (0.05–0.73), without any prominent C (t) value shift or dropouts in the SARS‐COV‐2 B.1.351 RNA control. Using the consensus criterion as the reference standard, 89 samples were positive, whereas 160 were negative. The overall clinical performance of rRT‐PCR assays was comparable (sensitivity 98.88%–100%; specificity 99.38%–100%), whereas the sensitivities of each target gene were more variable. CONCLUSIONS: The three rRT‐PCR assays showed comparable analytical sensitivity and clinical performance. The analytical and clinical sensitivities of each target gene were influenced more by the primer and probe design than the target gene itself.

Coronavirus disease 2019 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 Prompt and accurate detection of SARS-CoV-2 is crucial to prevent its transmission and administer the appropriate treatment. SARS-CoV-2 RNA detection using real-time reverse-transcription PCR (rRT-PCR) is the standard diagnostic test for current infections of COVID-19. 2 Various rRT-PCR assays are currently used worldwide, and the assays target different genes of the SARS-CoV-2, such as the envelope (E), ORF1ab/ RNA-dependent RNA polymerase (RdRp), nucleocapsid (N), and spike (S) genes. [3] [4] [5] rRT-PCR assays targeting more than one position of the SARS-CoV-2 genome are recommended because of potential genetic variation in SARS-CoV-2, which may result in false-negative results. 2 Since the emergence of SARS-CoV-2, sets of mutations have been noted, and these genetic mutations can affect the performance of the rRT-PCR assay. Mutation analysis of the SARS-CoV-2 genome collected worldwide showed that mutations occurred in all SARS-CoV-2 diagnostic targets. 6, 7 Moreover, novel strains with two amino acid (H69 and V70) deletion within the S gene, which includes the alpha variant of SARS-CoV-2 B.1.1.7 lineage, have been characterized by the S gene dropout in SARS-CoV-2 rRT-PCR assays targeting the S gene. 8, 9 Several novel mutations in either the E or N gene have been shown to affect SARS-CoV-2 rRT-PCR results. 10, 11 The beta variant of SARS-CoV-2 B.1.351 lineage, initially detected in South Africa, 12 is rapidly taking over the wild-type SARS-CoV-2 globally, with increased transmissibility. [12] [13] [14] The impact of the beta variant of SARS-CoV-2 B.1.351 lineage on the performance of SARS-CoV-2 rRT-PCR assays has not been fully elucidated. Because the primer and probe sequence information of commercial SARS-CoV-2 rRT-PCR assays are not available, performance evaluation using various clinical samples is important.

The target gene of SARS-CoV-2 rRT-PCR varies widely. The guidelines regarding target genes for SARS-CoV-2 detection differ worldwide. With the emergence of SARS-CoV-2, the World Health Organization recommended protocols targeting the E gene for screening and the RdRp gene for confirmation testing. 15 The US Centers for Disease Control and Prevention designed a 2019-nCoV rRT-PCR diagnostic panel targeting different regions of the N gene. 16 Among the target genes of the developed SARS-CoV-2 rRT-PCR assays, the N gene is the most frequently selected target gene apart from ORF1ab, whereas the S gene is the least frequently selected target gene. 5 Recently, the Allplex SARS-CoV-2/FluA/FluB/RSV assay (Seegene), targeting the S, RdRp, and N genes for SARS-CoV-2 detection, have been developed. The previously introduced SARS-CoV-2 rRT-PCR assay by Seegene, namely, Allplex 2019-nCoV assay, which was approved for emergency use with authorization from the US Food and Drug Administration, has been designed to include the E gene instead of the S gene as the target gene for SARS-CoV-2 detection. Here, we report the analytical sensitivity and clinical performance (sensitivity and specificity) of the Allplex SARS-CoV-2/FluA/FluB/RSV assay in comparison with two commercially available kits: the Standard M nCoV real-time detection kit (SD Biosensor, Osong, Korea) and U-TOP COVID-19 detection kit (Seasun Biomaterials). We also examined the potential impact of the SARS-CoV-2 variant of concern, particularly the B.1.351 lineage, on the analytical and clinical performance. were diluted to obtain eight concentrations as follows: 13, 130, 650, 1300, 13,000, 130,000, 1,300,000, and 13,000,000 copies/ml to analyze the linearity and amplification efficiency of each target of the rRT-PCR assay. The preliminary limit of detection (LoD) was determined with three replicates over five concentrations ranging from 13 to 13,000 copies/ml. At the concentration level spanning the possible LoD, each concentration was replicated five times.

RNA extraction from clinical samples was performed using the nucleic acid extraction platform Microlab STARlet (Hamilton). Allplex SARS-CoV-2/FluA/FluB/RSV assay, Standard M nCoV real-time detection kit, and U-TOP COVID-19 detection kit were used in this study. PCRs for all three rRT-PCR assays were performed using the CFX96 system (Bio-Rad).

The Allplex SARS-CoV-2/FluA/FluB/RSV assay has three targets for SARS-CoV-2, namely, the S, RdRp, and N genes. PCR was per- 

The clinical performance of the three rRT-PCRs was evaluated using reference standards. The reference standard was defined using the consensus criterion, which was obtained from two out of three rRT-PCR assays. 17, 18 The results were considered discordant when one of the rRT-PCR assays did not agree with the other two assays. The difference in C t values between the targets was analyzed using Student's t test. Linearity was assessed using linear regression analysis, and the amplification efficiency was evaluated as previously described. 4 

The LoD was determined using a positive-rate analysis and defined as the lowest concentration at which all replicates showed positive results (100% detection rate). Statistical significance was set at p < 0.05. All statistical analyses and visualizations were performed using the R software (version 3.4.3). rRT-PCR assays were between 80% and 120% for both RNA controls, which was consistent with the criteria for efficient multiplex rRT-PCR ( Figure 2 ). 19 At the concentration level of 13-13,000 copies/ml, for the SARS-CoV-2 RNA control, the LoD for the target genes was estimated to be 1300 copies/ml in all three assays (Table S1 ). The LoD of each target Viral RNA (log 10 copies/mL) 

Ct value N-Allplex RdRp-Allplex S-Allplex (A) (B)

All samples were analyzed using the Allplex SARS-CoV-2/FluA/ We investigated whether the difference in positivity among the targets in each assay was affected by the difference in C t values. The C t value distributions of the clinical samples are shown in Table 2 and 

Among the 249 samples, 6 (2.41%) samples showed discordant results between the rRT-PCR assays (Table 3) 

The clinical performance of SARS-CoV-2 rRT-PCR assays was evaluated for the overall results and for each target gene. As described above, the clinical performance was evaluated according to the ref- Note: The clinical performance was evaluated based on the reference standard results, which was defined by the consensus criterion.

Abbreviations: CI, confidence interval; C t , cycle threshold; SD, standard deviation yielded negative results by both Standard M nCoV real-time detection kit and U-TOP COVID-19 detection kit, which was later con- ificities of each target gene in the three assays showed high specificities ranging from 99.38% to 100% (Table 2 ).

The overall analytical sensitivity evaluation of all rRT-PCR assays showed comparable performance, whereas the analytical sensitivi- 

No.

Result target genes were included in each assay more than once. All rRT-PCR assays were performed using the same RNA extraction system, and the same amount of eluate was added to the reaction (all 10 µl), and therefore, the same effective sample volume was achieved. 21 When we directly compared the analytical sensitivities of each tar- 

None.

The authors declare no conflicts of interest.

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

World Health Organization, Coronavirus disease (COVID-19) outbreak

World Health Organization. Diagnostic Testing for SARS-CoV-2: Interim Guidance

Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea

Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets

FIND, the global alliance for diagnostics

Mutations on COVID-19 diagnostic targets

Comparative performance of SARS-CoV-2 detection assays using seven different primerprobe sets and one assay kit

S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral load in samples tested by TaqPath polymerase chain reaction

S Gene Dropout patterns in SARS-CoV-2 tests suggest spread of the H69del/V70del mutation in the US

A recurrent mutation at Position 26340 of SARS-CoV-2 is associated with failure of the E Gene quantitative reverse transcription-PCR utilized in a commercial dual-target diagnostic assay

SARS-CoV-2 samples may escape detection because of a single point mutation in the N gene

Detection of a SARS-CoV-2 variant of concern in South Africa

The SARS-CoV-2 B.1.351 lineage (VOC β) is outgrowing the B.1.1.7 lineage (VOC α) in some French regions in

Detection of B.1.351 SARS-CoV-2 variant Strain-Zambia

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Centers for Disease Control and Prevention, novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. CDC

Comparison of four molecular in vitro diagnostic assays for the detection of SARS-CoV-2 in nasopharyngeal specimens

Evaluation of three commercial assays for SARS-CoV-2 molecular detection in upper respiratory tract samples

Guidelines for validation of qualitative real-time PCR methods

Optimization of primer sets and detection protocols for SARS-CoV-2 of coronavirus disease 2019 (COVID-19) using PCR and real-time PCR

Direct comparison of SARS-CoV-2 analytical limits of detection across seven molecular assays

False positive results with SARS-CoV-2 RT-PCR tests and how to evaluate a RT-PCR-positive test for the possibility of a false positive result

Impact of false-positives and false-negatives in the UK's COVID-19 RT-PCR testing programme. Government Office for Science; 2020

Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples

Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19

Duration of culturable SARS-CoV-2 in hospitalized patients with Covid-19

Polymerase chain reaction assays reverted to positive in 25 discharged patients with COVID-19

Temporal dynamics in viral shedding and transmissibility of COVID-19

The laboratory diagnosis of coronavirus disease 2019-frequently asked questions

SARS-CoV-2 N gene dropout and N gene Ct value shift as indicator for the presence of B.1.1.7 lineage in a commercial multiplex PCR assay